Candesartan
- Generic Name
- Candesartan
- Brand Names
- Atacand, Atacand Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H20N6O3
- CAS Number
- 139481-59-7
- Unique Ingredient Identifier
- S8Q36MD2XX
- Background
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.
- Indication
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction an...
- Associated Conditions
- Hypertension, NYHA Functional Class II-IV Heart Failure
- Associated Therapies
- -
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
- Conditions
- Interventions
- First Posted Date
- 2010-02-04
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 80
- Registration Number
- NCT01062451
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States
Impact of Diabetes on Left Ventricular Remodeling
- Conditions
- Interventions
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 72
- Registration Number
- NCT01052272
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2012-04-25
- Lead Sponsor
- Kaiser Permanente
- Registration Number
- NCT00930995
- Locations
- 🇺🇸
Kaiser Permanente, Sacramento, California, United States
Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal
- Conditions
- Interventions
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00905333
- Locations
- 🇧🇷
Research Site, Americana, Brazil
Candesartan Versus Propranolol for Migraine Prevention
- Conditions
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 72
- Registration Number
- NCT00884663
- Locations
- 🇳🇴
Norwegian National Headache Centre, St. Olavs University Hospital, Trondheim, Norway
Bioequivalence Study in Healthy Subjects
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00844324
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 22
- Registration Number
- NCT00775840
The Potential of Candesartan to Retard the Progression of Aortic Stenosis
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2009-05-19
- Lead Sponsor
- University of Helsinki
- Target Recruit Count
- 120
- Registration Number
- NCT00699452
- Locations
- 🇫🇮
Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland
Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT00690612
- Locations
- 🇺🇦
Research Site, Kyiv, Ukraine
Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00679640
- Locations
- 🇫🇷
Research Site, Maisons Laffitte, Yvelines, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.